TMDX vs. SNN, SOLV, PEN, STVN, IRTC, BLCO, GKOS, SLNO, NVST, and WRBY
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), Soleno Therapeutics (SLNO), Envista (NVST), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.
TransMedics Group vs. Its Competitors
TransMedics Group (NASDAQ:TMDX) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
In the previous week, TransMedics Group had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for TransMedics Group and 5 mentions for Smith & Nephew SNATS. TransMedics Group's average media sentiment score of 1.07 beat Smith & Nephew SNATS's score of 0.10 indicating that TransMedics Group is being referred to more favorably in the media.
TransMedics Group has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group. Smith & Nephew SNATS is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
TransMedics Group has a net margin of 13.49% compared to Smith & Nephew SNATS's net margin of 0.00%. TransMedics Group's return on equity of 28.02% beat Smith & Nephew SNATS's return on equity.
99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
TransMedics Group currently has a consensus target price of $125.40, indicating a potential upside of 8.87%. Smith & Nephew SNATS has a consensus target price of $36.00, indicating a potential upside of 0.66%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Smith & Nephew SNATS.
Summary
TransMedics Group beats Smith & Nephew SNATS on 14 of the 17 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransMedics Group Competitors List
Related Companies and Tools
This page (NASDAQ:TMDX) was last updated on 10/8/2025 by MarketBeat.com Staff
